VYNE Therapeutics (VYNE) Retained Earnings (2016 - 2025)
VYNE Therapeutics (VYNE) posted Retained Earnings of -$757.7 million for Q4 2025, down 196.59% on a QoQ basis from $784.4 million in Q2 2025, and down 3788365.0% year-over-year from N/an in Q4 2024.
VYNE Therapeutics (VYNE) Retained Earnings (2016 - 2025) Analysis & Trends
VYNE Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$757.7 million for Q4 2025.
- Quarterly Retained Earnings fell 3788365.0% year-over-year to -$757.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$757.7 million (down 3788365.0% YoY) and the FY2025 annual result came in at -$757.7 million, down 3788365.0% from the prior year.
- Retained Earnings was -$757.7 million for Q4 2025 at VYNE Therapeutics, down from $784.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $784.4 million in Q2 2025 and bottomed at -$757.7 million in Q4 2025.
- A 5-year average of -$45.2 million and a median of -$293.4 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 226.49% — and 2025, when it slumped 3788365.0%.
- VYNE Therapeutics' Retained Earnings stood at $688.2 million in 2021, then tumbled by 194.86% to -$652.8 million in 2022, then soared by 100.0% to $26000.0 in 2023, then slipped by 23.08% to $20000.0 in 2024, then slumped by 3788365.0% to -$757.7 million in 2025.
- Business Quant data shows VYNE's Retained Earnings at -$757.7 million in Q4 2025, $784.4 million in Q2 2025, and -$739.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -622,000.00 |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -757.65 Mn |
| Jun 30, 2025 | 784.42 Mn |
| Mar 31, 2025 | -739.78 Mn |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 782.65 Mn |
| Jun 30, 2024 | 781.92 Mn |
| Mar 31, 2024 | 781.02 Mn |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | -685.15 Mn |
| Jun 30, 2023 | -678.56 Mn |
| Mar 31, 2023 | -668.51 Mn |
| Sep 30, 2022 | -652.80 Mn |
| Jun 30, 2022 | 691.68 Mn |
| Mar 31, 2022 | -634.90 Mn |
| Dec 31, 2021 | 688.16 Mn |
| Sep 30, 2021 | 686.84 Mn |
| Jun 30, 2021 | -606.67 Mn |
| Mar 31, 2021 | -586.75 Mn |
| Dec 31, 2020 | 603.69 Mn |
| Sep 30, 2020 | -543.00 Mn |